Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics announced additional positive Phase 1 data for its lead asset ELVN-001 in chronic myeloid leukemia (CML), which will be presented at the EHA 2026 Congress. The data show a 69% Major Molecular Response (MMR) rate in the randomized 60 mg and 120 mg cohorts and a 52% MMR rate in patients previously treated with asciminib, with a favorable safety profile maintained across 141 patients.
Key figures
- Drug Name
- ELVN-001
- Phase Of Trial
- Phase 1
- Patients enrolled
- 141
- MMR rate 80mg cohort
- 47%
- Discontinuation rate
- 6.4%
- MMR rate 60 120mg cohort
- 69%
- MMR rate prior asciminib
- 52%
- Median treatment duration weeks
- 31.7
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.